A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

a twice-daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score ...

The other single-inhaler on the market for COPD triple therapy, fluticasone-umeclidinium-vilanterol, is a dry-powder inhaler that does not contain hydrofluoroalkane-134a. In a 2024 JAMA report ...

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first ...

Doses of fluticasone propionate inhalation powder 50 and 100 mcg twice daily significantly improved FEV1 (15% and 18% change from baseline at Endpoint, respectively) compared with placebo (7% change).

A total of 332 patients entered the study and 277 patients were randomised and treated, 137 with FP250µg twice daily via Diskus TM inhaler and ... for each treatment [fluticasone propionate ...

R. Backman, Lohjan Aluesairaala, Keuhkopoliklinikka, Sairaalantie, Lohja, Finland; C. Baumgarten, Abteilung für Klinische Immunologie und Asthma Poliklinik im Rudolf ...